Dr. Miguel A. Islas-Ohlmayer, MD

Dr. Islas-Ohlmayer practices at St. Elizabeth Healthcare Edgewood Hospital in Edgewood, Kentucky, part of Diocese of Covington.

Dr. Islas-Ohlmayer's NPI, 1295917425, was assigned on November 29, 2007. Dr. Islas-Ohlmayer holds Kentucky license 57685.

Dr. Islas-Ohlmayer's primary practice is St. Elizabeth Healthcare Edgewood Hospital, at 1 Medical Village Drive, Edgewood, KY 41017 in Kenton County. The practice phone is (859) 301-2000.

Dr. Islas-Ohlmayer's primary practice is St. Elizabeth Healthcare Edgewood Hospital in Edgewood, Kentucky, part of Diocese of Covington. Dr. Islas-Ohlmayer is also affiliated with St. Elizabeth Healthcare Florence Hospital. The medical group on file is St. Elizabeth Physicians. Dmand AI also links Dr. Islas-Ohlmayer to 3 more hospitals, 1 skilled nursing facility and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Islas-Ohlmayer practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Islas-Ohlmayer's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Islas-Ohlmayer's licenses on file in 2 states: Kentucky and Ohio.

CMS data shows 1,107 Medicare services from Dr. Islas-Ohlmayer across 9 procedure codes in 2024, for 216 Medicare patients. Medicare paid $60,228 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 216 Medicare patients who saw Dr. Islas-Ohlmayer in 2024. The largest group is 65 to 74, with 97 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Islas-Ohlmayer's median patient age at 71, with 51% women.

In 2024, Dr. Islas-Ohlmayer wrote 959 Medicare Part D claims for 104 patients. 79% of them were for generic drugs. CMS names the drug for 774 of them, across 29 drugs with 11 or more claims each, at $2,730,225 in total drug cost. In 2023, CMS named 669 claims across 28 drugs.

Dr. Islas-Ohlmayer accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Islas-Ohlmayer, published from 2018 to 2020. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin and Hodgkin Disease. Dr. Islas-Ohlmayer has published most often in Blood. Dr. Islas-Ohlmayer's most frequent co-authors are Ranjana Advani, MD, Edward D. Agura, MD and Stephen M. Ansell, MD.

Dmand AI links Dr. Islas-Ohlmayer to 7 clinical trials, 3 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Lymphoma, B-Cell, Hodgkin Disease and Leukemia, Lymphocytic, Chronic, B-Cell. Loxo Oncology, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Islas-Ohlmayer that name 1 trial.

CMS Open Payments shows 288 general payments to Dr. Islas-Ohlmayer from 39 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 69% of the total. Rigel Pharmaceuticals, Inc. paid the most, $19,680. It also lists 7 research payments totaling $41,746 from 2016 to 2025, naming 1 clinical trial.